PTC Therapeutics (PTCT)
(Delayed Data from NSDQ)
$36.16 USD
+0.68 (1.92%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $36.12 -0.04 (-0.11%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum D VGM
Cash flow Statements
Fiscal Year End for PTC Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -626.60 | -559.02 | -523.90 | -438.16 | -251.58 |
Depreciation/Amortization & Depletion | 454.06 | 165.83 | 71.28 | 86.30 | 30.95 |
Net Change from Assets/Liabilities | -4.00 | -94.94 | -23.79 | 36.91 | 20.43 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 18.13 | 131.46 | 225.08 | 120.88 | 101.56 |
Net Cash From Operating Activities | -158.42 | -356.65 | -251.33 | -194.07 | -98.64 |
Property & Equipment | -28.44 | -32.02 | -28.21 | -17.84 | -13.76 |
Acquisition/ Disposition of Subsidiaries | -92.18 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -56.12 | 442.64 | 304.51 | -505.57 | -341.80 |
Other Investing Activities | 0.00 | -120.44 | -57.12 | -38.13 | -31.68 |
Net Cash from Investing Activities | -176.74 | 290.18 | 219.18 | -561.55 | -387.24 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 29.99 | 71.08 | 23.10 | 103.57 | 345.61 |
Issuance (Repayment) of Debt | -301.38 | 148.72 | -2.22 | 603.84 | 267.60 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 917.79 | -51.85 | 0.00 | -38.70 | 0.00 |
Net Cash from Financing Activities | 646.40 | 167.95 | 20.88 | 668.72 | 613.21 |
Effect of Exchange Rate Changes | 3.11 | -2.77 | -7.82 | 7.69 | -1.30 |
Net Change In Cash & Equivalents | 314.36 | 98.71 | -19.09 | -79.22 | 126.03 |
Cash at Beginning of Period | 295.93 | 197.22 | 216.31 | 295.53 | 169.50 |
Cash at End of Period | 610.28 | 295.93 | 197.22 | 216.31 | 295.53 |
Diluted Net EPS | -8.37 | -7.79 | -7.43 | -6.64 | -4.27 |
Fiscal Year End for PTC Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -190.76 | -91.58 | -626.60 | -470.81 | -337.84 |
Depreciation/Amortization & Depletion | 56.01 | 51.99 | 454.06 | 375.17 | 312.54 |
Net Change from Assets/Liabilities | 54.33 | 65.51 | -4.00 | 78.61 | 71.10 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 79.72 | 44.83 | 18.13 | -41.10 | -89.41 |
Net Cash From Operating Activities | -0.69 | 70.76 | -158.42 | -58.13 | -43.61 |
Property & Equipment | 25.83 | -9.59 | -28.44 | -22.87 | -16.52 |
Acquisition/ Disposition of Subsidiaries | -54.76 | 0.00 | -92.18 | 0.00 | 0.00 |
Investments | -151.92 | -50.58 | -56.12 | 9.84 | 10.23 |
Other Investing Activities | 0.00 | -54.76 | 0.00 | -69.29 | -46.44 |
Net Cash from Investing Activities | -180.86 | -114.93 | -176.74 | -82.32 | -52.72 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 6.72 | 2.03 | 29.99 | 27.58 | 24.13 |
Issuance (Repayment) of Debt | -1.49 | -1.49 | -301.38 | -1.38 | -1.38 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 241.79 | 0.00 | 917.79 | -0.28 | -0.20 |
Net Cash from Financing Activities | 247.02 | 0.54 | 646.40 | 25.92 | 22.55 |
Effect of Exchange Rate Changes | -7.22 | -2.03 | 3.11 | 0.02 | 2.35 |
Net Change In Cash & Equivalents | 58.26 | -45.66 | 314.36 | -114.52 | -71.43 |
Cash at Beginning of Period | 610.28 | 610.28 | 295.93 | 295.93 | 295.93 |
Cash at End of Period | 668.54 | 564.62 | 610.28 | 181.41 | 224.50 |
Diluted Net EPS | -1.29 | -1.20 | -2.07 | -1.76 | -2.66 |